Literature DB >> 3896662

A double-blind, parallel study of tenoxicam and piroxicam in patients with osteoarthrosis.

H A Bird, J Hill, J S Dixon, D Looi, V Wright.   

Abstract

A double-blind, parallel group study was carried out in 30 patients with osteoarthrosis to compare the efficacy and tolerance of tenoxicam (40 mg/day) and piroxicam (40 mg/day) given over a period of 4 weeks. All had previously been treated with a variety of non-steroidal anti-inflammatory agents and/or analgesics. Patients were allocated at random to one or other treatment group. Clinical and laboratory assessments were made on entry and after 2 and 4 weeks of treatment. The results showed that both drugs improved general pain, the improvement being somewhat greater with tenoxicam. Little change was noted in other symptoms with either treatment. Side-effects reported were mainly gastro-intestinal. Six of the 15 piroxicam-treated patients stopped treatment because of adverse reactions, 1 because of treatment failure and 1 because he preferred previous treatment. Three of the 15 tenoxicam-treated patients discontinued because of adverse reactions. The remaining patients (7 on piroxicam and 12 on tenoxicam) elected at the end of the trial period to remain on their respective treatment instead of their previous medication.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896662     DOI: 10.1185/03007998509109630

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses.

Authors:  R J Francis; J G Allen; D Looi; J S Dixon; H A Bird; V Wright
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

Review 2.  Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; P A Todd
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  The evaluation of a nonsteroidal anti-inflammatory drug (tenoxicam) in the treatment of sleep disturbance in osteoarthritic patients.

Authors:  T J Leigh; H A Bird; I Hindmarch; V Wright
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.